Mirikizumab vs standard treatment for newly diagnosed ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ulcerative colitis within the last 12 months.
- Your disease is moderate to severe and has not responded well enough to 5-ASA medications (like mesalamine) or steroids.
- You have never taken azathioprine, 6-MP, or advanced therapies (biologics or JAK inhibitors) before.
- You are willing to undergo colonoscopies and fill out a daily diary.
- You do not have Crohn's disease, active infections like hepatitis or tuberculosis, or a history of cancer (except non-melanoma skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study tests a medication called mirikizumab (an injection) in people over 60 with moderate to severe Crohn's disease or ulcerative colitis. The goal is to see if it effectively reduces inflammation and helps symptoms, while also checking how safe it is for older adults.
This study looks at whether a special ultrasound test can better track how well a treatment called mirikizumab is working for people with moderate-to-severe ulcerative colitis. It may help doctors see if the treatment is reducing inflammation in the bowel more accurately than current methods.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This study compares two treatment approaches for newly diagnosed moderate-to-severe Crohn's disease: a powerful biologic called mirikizumab given early (top-down) versus the standard approach with azathioprine. The goal is to see if starting with the stronger treatment leads to better control of inflammation and symptoms.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.